Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) Agonists
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c02183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Kenneth L Granberg und 17 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Mö…. Hauptthemen laut MEDLINE: Relaxin. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: AstraZeneca M?lndal, Mitsubishi Tanabe Pharma Corporation.
Abstract (Originalsprache)
Relaxin H2 is a clinically relevant peptide agonist for relaxin family peptide receptor 1 (RXFP1), but a combination of this hormone's short plasma half-life and the need for injectable delivery limits its therapeutic potential. We sought to overcome these limitations through the development of a potent small molecule (SM) RXFP1 agonist. Although two large SM HTS campaigns failed in identifying suitable hit series, we uncovered novel chemical space starting from the only known SM RXFP1 agonist series, represented by ML290. Following a design-make-test-analyze strategy based on improving early dose to man ranking, we discovered compound 42 (AZ7976), a highly selective RXFP1 agonist with sub-nanomolar potency. We used AZ7976, its 10 000-fold less potent enantiomer 43 and recombinant relaxin H2 to evaluate in vivo pharmacology and demonstrate that AZ7976-mediated heart rate increase in rats was a result of RXFP1 agonism. As a result, AZ7976 was selected as lead for continued optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Mölndal 43183, Sweden.
- Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 1000 Kamoshida-cho, Aoba-ku, Yokohama, Kanagawa 227-0033, Japan.
- Drug Metabolism and Pharmacokinetics (DMPK), Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden.
- Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden.
- Cardiovascular, Renal and Metabolism Safety, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden.
- Regulatory Toxicology & Safety Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
ORCID-Profile: Kenneth L Granberg
Förderung
- AstraZeneca M?lndal
- Mitsubishi Tanabe Pharma Corporation
Zitieren
APA
Granberg, K. L., Sakamaki, S., Fuchigami, R., Niwa, Y., Fujio, M., Kato, H., Bergström, F., Larsson, N., Persson, M., Villar, I. C., Fujita, T., Sugikawa, E., Althage, M., Yano, N., Yokoyama, Y., Kimura, J., Lal, M., & Mochida, H. (2024). Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) Agonists. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c02183
Vancouver
Granberg KL, Sakamaki S, Fuchigami R, Niwa Y, Fujio M, Kato H, et al. Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) Agonists. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c02183
BibTeX
@article{Granberg2024,
author = {Granberg, Kenneth L and Sakamaki, Shigeki and Fuchigami, Ryuichi and Niwa, Yasuki and Fujio, Masakazu and Kato, Harutoshi and Bergström, Fredrik and Larsson, Niklas and Persson, Mikael and Villar, Inmaculada C and Fujita, Takuya and Sugikawa, Emiko and Althage, Magnus and Yano, Naoko and Yokoyama, Yoshito and Kimura, Junpei and Lal, Mark and Mochida, Hideki},
title = {Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) Agonists},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c02183}
}
EUVIMED